HOME › Laboratory
Director's Message
National Institute of Biomedical Innovation Message from the Director General
The National Institute of Biomedical Innovation (NIBIO) was established in April 2005, in the International Culture Park, Saito, Ibaragi City, Osaka, for the purpose to contribute to the creation of the innovative pharmaceuticals and the improvement of the national health.
According to the first term plan, from FY2005 until now, we performed three primary functions, 1. Fundamental Technological Research, 2. Bioresources Research, 3. R&D promotion service, to reduce our achievement to society, serving as a "Mediator" between the basic research performed at universities and the application of such research carried out by private corporations.
In addition, we have promoted the action with close collaboration of organizations across industry, government and academia by making use of our strong point to be the only organization in Japan that performs totally by one stop "research, resources, and funding" with regard to the fundamental technologies such as the research and development of pharmaceuticals.
In this way, in the first term that lasted until FY2009, we were able to obtain epoch-making results of research, such that the world's greatest database of toxicogenomics was constructed and that two research themes (infectious disease vaccine, iPS cells drug development and application) led by NIBIO were adopted in "Super Special Consortia for supporting the development of cutting-edge medical care".
In the second term plan that began in FY2010, we promote the reinforcement of "Mediation function", making further great progress of autonomy, flexibility, and the power of winning the competitions as the research institute on the basis of the previous achievement.
We changed each name of the departments in our organization as following for the second term, 1. Department of Fundamental Technical Research, 2. Department of Disease Bioresources Research, 3. Department of Research and Development Promotion. Especially, we emphasize the importance of the rare diseases research and initiated bank for rare diseases to offer resources easily to the researchers of the whole country and to make good use of the database to the immediate treatment study of the rare diseases. Furthermore, we promote eagerly following three fields as the key domain, 1. Next-generation vaccines, 2. Development of a drug toxicity testing system, 3. Treatment of the rare diseases.
Our activities will be tied to the development of "Innovative pharmaceuticals from Japan" which become the base for "The safe society in which people feel relieve", and we want to develop still more as a core center of the Japanese "Life innovation".
The close collaboration of organizations across industry, government and academia is necessary for the coordinated development of new medical technologies. Therefore, while collaborating with the administration, the clinical spot, and the local government, in addition to industry such as pharmaceutical companies and academia such as universities, we are committed to carry out opening innovation and contribute to people and society. We look forward to your continuous support, understanding and collaboration.
Koichi Yamanishi